Robyn Karnauskas
Stock Analyst at Truist Securities
(2.18)
# 1,524
Out of 4,667 analysts
179
Total ratings
40.8%
Success rate
-5.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $132 → $130 | $97.69 | +33.08% | 10 | Nov 7, 2024 | |
| AMGN Amgen | Downgrades: Hold | $320 → $333 | $287.87 | +15.68% | 11 | Oct 14, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $88.63 | -6.35% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $167.76 | +25.18% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $6.28 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $156.00 | +117.95% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $3.70 | +602.70% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $1.10 | +536.36% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $743.35 | +52.69% | 16 | Apr 3, 2024 | |
| OABI OmniAb | Maintains: Buy | $10 | $3.90 | +156.41% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.68 | +235.82% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $24.00 | +208.33% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.49 | +100.17% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $26.17 | +83.42% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $14.70 | +240.14% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $753.41 | +12.82% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $448.00 | +13.39% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $24.84 | +44.93% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $58.07 | +44.65% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $41.96 | -40.42% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.59 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $62.56 | +123.79% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $1.28 | +11,618.75% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $2.22 | +215.32% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $5.70 | +864.91% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.80 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.67 | +986.14% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $23.36 | +1,269.86% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $5.79 | +159.07% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.28 | +662.20% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $9.43 | +801.38% | 1 | Oct 8, 2020 |
Merck & Co.
Nov 7, 2024
Maintains: Buy
Price Target: $132 → $130
Current: $97.69
Upside: +33.08%
Amgen
Oct 14, 2024
Downgrades: Hold
Price Target: $320 → $333
Current: $287.87
Upside: +15.68%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $88.63
Upside: -6.35%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $167.76
Upside: +25.18%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $6.28
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $156.00
Upside: +117.95%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $3.70
Upside: +602.70%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.10
Upside: +536.36%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $743.35
Upside: +52.69%
OmniAb
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.90
Upside: +156.41%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.68
Upside: +235.82%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $24.00
Upside: +208.33%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.49
Upside: +100.17%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.17
Upside: +83.42%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $14.70
Upside: +240.14%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $753.41
Upside: +12.82%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $448.00
Upside: +13.39%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $24.84
Upside: +44.93%
Oct 6, 2023
Reiterates: Buy
Price Target: $84
Current: $58.07
Upside: +44.65%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $41.96
Upside: -40.42%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.59
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $62.56
Upside: +123.79%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $1.28
Upside: +11,618.75%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $2.22
Upside: +215.32%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $5.70
Upside: +864.91%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.80
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.67
Upside: +986.14%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $23.36
Upside: +1,269.86%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $5.79
Upside: +159.07%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.28
Upside: +662.20%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $9.43
Upside: +801.38%